Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab in pediatric plaque psoriasis
NCT04435600Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2020
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of risankizumab in plaque psoriasis, sponsored by AbbVie Inc.. Started Jul 2020; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04435600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04435600.